Marc Roelke, MD
Clinical Cardiac Electrophysiology · West Orange, NJNPI 1851391429
Payments from drug & device makers
Across 531 payments — averaging $274.72 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Abbott$93K
- Boston Scientific$16K
- Johnson & Johnson$13K
- Medtronic$12K
- Boehringer Ingelheim$5K
- Pfizer$3K
- plus $4K from 30 others
Across 1 payment — averaging $475.00 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Medtronic$475
What the payments were for
- Consulting fees$82,63875%
- Speaking & faculty fees$14,48113%
- Travel & lodging$5,5525%
- Food & beverage$7,1186%
- Education$200%
- Entertainment$640%
- Other$120%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Abbott | 106 | $93,404 |
| Boston Scientific | 44 | $16,343 |
| Johnson & Johnson | 41 | $13,172 |
| Medtronic(2 entities) | 141 | $11,547 |
| Boehringer Ingelheim | 3 | $4,698 |
| Pfizer | 25 | $3,044 |
| E.r. Squibb & Sons, L.L.C. | 22 | $1,058 |
| Novartis | 54 | $541 |
| Amgen | 20 | $317 |
| Novo Nordisk | 12 | $209 |
| Altathera Pharmaceuticals LLC | 4 | $192 |
| Biotronik Inc. | 3 | $183 |
| Philips North America LLC | 3 | $126 |
| Amarin Pharma, Inc. | 9 | $122 |
| Kestra Medical Technology Services, Inc. | 5 | $116 |
| Cvrx, Inc. | 3 | $75 |
| Irhythm Technologies, Inc. | 4 | $66 |
| Stereotaxis Inc | 1 | $64 |
| Impulse Dynamics (USA) Inc. | 3 | $59 |
| Kiniksa Pharmaceuticals, Ltd. | 4 | $55 |
| Baxter Healthcare | 1 | $54 |
| Davol Inc. | 1 | $47 |
| Itamar Medical Inc | 2 | $47 |
| Alnylam Pharmaceuticals Inc. | 3 | $47 |
| Atricure, Inc. | 2 | $40 |
| Bayer | 2 | $39 |
| ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) | 2 | $37 |
| Sanofi-aventis U.S. LLC | 2 | $32 |
| Kiniksa Pharmaceuticals International, PLC | 2 | $31 |
| Biosense Webster, Inc. | 1 | $31 |
| Lundbeck LLC | 1 | $15 |
| Vital Connect, Inc | 1 | $14 |
| Azurity Pharmaceuticals, Inc. | 1 | $13 |
| Welch Allyn | 1 | $12 |
| Cardiva Medical, Inc. | 1 | $12 |
| Vivaquant Inc, Dba Rhythm Express | 1 | $10 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- ENSITE PRECISION$29,475
- Optisure Defibrillation ICD Lead$13,275
- XARELTO$12,565
- EMBLEM S ICD ELECTRODE DELIVERY SYSTEM$9,091
- EnSite Precision Cardiac Mapping System$7,538
- Quartet CRT Lead$4,050
- GENERAL BRADY$3,600
- ELIQUIS$3,481
- GENERAL - THERAPIES$2,758
- CardioMEMS HF System$2,700
- Nanostim Leadleas Pacemaker$1,575
- AVEIR$1,123
- Quadra Allure MP RF CRT Pacemkr$900
- Watchman$269
- WATCHMAN FLX$150
How this compares
$145,874 in reported general payments places this provider in the 85th percentile of 102 clinical cardiac electrophysiology providers in New Jersey.
See all clinical cardiac electrophysiology providers in New Jersey →
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 99 | $106,116 |
| XareltoRivaroxaban | 26 | $25,640 |
| EntrestoSacubitril/Valsartan | 22 | $20,456 |
| Coreg CrCarvedilol Phosphate | 12 | $14,295 |
| JardianceEmpagliflozin | 13 | $10,674 |
| PradaxaDabigatran Etexilate Mesylate | 21 | $3,883 |
| Amiodarone Hcl | 83 | $2,398 |
| Metoprolol Succinate | 129 | $1,857 |
| Flecainide Acetate | 16 | $835 |
| Carvedilol | 67 | $819 |
| SotalolSotalol Hcl | 34 | $657 |
| Diltiazem 24hr Er (Cd)Diltiazem Hcl | 24 | $604 |
| Atorvastatin Calcium | 48 | $462 |
| Losartan Potassium | 32 | $410 |
| Rosuvastatin Calcium | 33 | $339 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis | $3,044 | $106,11699 claims |
| Johnson & JohnsonXarelto | $13,172 | $25,64026 claims |
| NovartisEntresto | $541 | $20,45622 claims |
| Boehringer IngelheimJardiance, Pradaxa | $4,698 | $14,55834 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 102 clinical cardiac electrophysiology providers in New Jersey.
Other clinical cardiac electrophysiology in West Orange
- David DobeshWest Orange$96K
- Donald RubensteinWest Orange$48K
- Edward KoganWest Orange$24K
- Suneet MittalParamus$2.3M
- Benjamin D SouzaCherry Hill$1.2M
- George MarkHaddon Heights$935K
- Sanjeev SaksenaWarren$911K
- Darius SholevarCherry Hill$843K
- Jonathan SteinbergRidgewood$490K
- Emad AzizNewark$350K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.